Factors Influencing a Specific Pathologic Diagnosis of Non-Small-Cell Lung Carcinoma

被引:6
|
作者
Sulpher, Jeffrey A. [1 ]
Owen, Scott P. [2 ]
Hon, Henrique [2 ]
Tobros, Kimberly [2 ]
Shepherd, Frances A. [2 ]
Sabri, Elham [3 ]
Gomes, Marcio [4 ]
Sekhon, Harman [4 ]
Liu, Geoffrey [2 ]
Canil, Christina M. [1 ]
Wheatley-Price, Paul [1 ]
机构
[1] Univ Ottawa, Dept Med, Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Med Oncol & Hematol,Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Ottawa, Res Inst, Ottawa Hosp, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Pathol & Lab Med, Ottawa Hosp, Ottawa, ON, Canada
关键词
Chart review; Diagnosis; Histology; Non-small-cell lung cancer; CANCER; CHEMOTHERAPY; MUTATIONS; GEFITINIB; CYTOLOGY; EGFR; ADENOCARCINOMA; CLASSIFICATION; CARBOPLATIN; PACLITAXEL;
D O I
10.1016/j.cllc.2012.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathologic subtyping of non-small-cell lung carcinoma is increasingly important when selecting therapy. The records of 739 patients were reviewed to identify factors associated with attaining a specific pathologic diagnosis. Only 456 (62%) of patients received a specific pathologic diagnosis, which was significantly associated with histologic biopsy samples, immunohistochemical testing, and diagnosis outside of an academic center. Introduction: Historically, a non-small-cell lung carcinoma diagnosis, without pathologic subclassification, provided sufficient information to guide therapy. Evidence now demonstrates that pathologic subtype classification is central in selecting optimal treatment. This review aimed to identify factors associated with a specific pathologic diagnosis. Methods: All nonoperative cases of non-small-cell lung carcinoma (NSCLC) referred to the medical oncology divisions of the Ottawa Hospital Cancer Centre (2008) and Princess Margaret Hospital, Toronto (2007-2010) were identified. The charts were reviewed for demographics, diagnostic methods, and final diagnosis. Logistic regression was performed to identify variables associated with a specific diagnosis. Results: Of 739 patient records analyzed, 377 (51%) were men, 299 (40%) were aged over 70 years, and 510 (69%) had an Eastern Cooperative Oncology Group performance status of 0-2. Three hundred and eighty five (52%) of patients were diagnosed in a tertiary academic center. The lung primary was sampled in 503 (68%) of patients. Computed tomography-guided biopsy (n = 370, 50%) and bronchoscopy (n = 179, 24%) were the most common techniques. Four hundred and seventy seven (65%) of biopsies were cytologic specimens alone, and immunohistochemistry was performed in 337 (46%) of cases. The most common diagnoses were adenocarcinoma (n = 338, 46%), NSCLC not otherwise specified (n = 254, 34%), and squamous cell carcinoma (n = 115, 16%). Overall, 456 (62%) of patients received a specific pathologic diagnosis. Factors significantly associated with attaining a specific pathologic diagnosis were diagnosis outside an academic center (adjusted odds ratios [OR] 2.1 [95% CI, 1.41-3.14]; P = .0003), histologic laboratory samples (adjusted OR 1.58 [95% CI, 1.003-2.49]; P = .049), and immunohistochemical testing (adjusted OR 1.82 [95% CI, 1.25-2.70], P = .0021). Conclusions: A significant minority of patients with NSCLC do not receive a specific pathologic diagnosis. In an era of individualized medicine, this may potentially impact optimal clinical management. Clinical Lung Cancer, Vol. 14, No. 3, 238-44 (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 50 条
  • [31] Novel ALK-specific mRNA in situ hybridization assay for non-small-cell lung carcinoma
    Hirai, Noriko
    Sasaki, Takaaki
    Okumura, Shunsuke
    Sado, Masatoshi
    Akiyama, Naoko
    Kitada, Masahiro
    Takei, Hidehiro
    Ohsaki, Yoshinobu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 257 - 268
  • [33] PREOPERATIVE STAGING OF NON-SMALL-CELL CARCINOMA OF THE LUNG - IMAGING METHODS
    QUINT, LE
    FRANCIS, IR
    WAHL, RL
    GROSS, BH
    GLAZER, GM
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1995, 164 (06) : 1349 - 1359
  • [34] Chemotherapy for non-small-cell lung carcinoma, a look at the past decade
    Monnerat, C
    Le Chevalier, T
    ANNALS OF ONCOLOGY, 2000, 11 (07) : 773 - 776
  • [35] Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond
    Dubey, Sarita
    Siegfried, Jill M.
    Traynor, Anne M.
    LANCET ONCOLOGY, 2006, 7 (05): : 416 - 424
  • [36] Overdosage of vinorelbine in a woman with metastatic non-small-cell lung carcinoma
    Lotz, JP
    Chapiro, J
    Voinea, A
    Cornu, P
    Pene, F
    Bazelly, B
    Similowski, T
    Derquenne, F
    ANNALS OF ONCOLOGY, 1997, 8 (07) : 714 - 715
  • [37] TUMOR STAGE IN NON-SMALL-CELL CARCINOMA OF THE LUNG .2.
    MOUNTAIN, CF
    GREENBERG, SD
    FRAIRE, AE
    CHEST, 1991, 99 (05) : 1258 - 1260
  • [38] INDUCTION CHEMOTHERAPY FOR NON-SMALL-CELL CARCINOMA OF THE LUNG - LIMITATIONS AND LESSONS
    COX, JD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (06): : 1375 - 1376
  • [39] L1CAM in non-small-cell lung carcinoma
    Hai, Josephine
    Zhu, Chang-Qi
    Der, Sandy
    Jurisica, Igor
    Tsao, Ming-Sound
    CANCER RESEARCH, 2011, 71
  • [40] Personalized medicine and treatment approaches in non-small-cell lung carcinoma
    Vadakara, Joseph
    Borghaei, Hossein
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2012, 5 : 113 - 123